Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 17;27(8):2073-2087.
doi: 10.1093/neuonc/noaf016.

Spatially resolved transcriptomics of benign and malignant peripheral nerve sheath tumors

Juliane Bremer  1 , Pamela Franco  2 , Joelle Aline Menstell  3   4   5 , Shelisa Tey  1 , Kamil Kajetan Zajt  1 , Klimentina Popzhelyazkova  1 , Kay Nolte  1 , Jürgen Schlegel  6 , Maria Teresa Pedro  7 , Anja Osterloh  8 , Daniel Delev  9   5 , Marc Hohenhaus  3   4 , Christoph Scholz  3   4 , Oliver Schnell  9 , Juergen Beck  3   4 , Joachim Weis  1 , Dieter Henrik Heiland  10   11   12   3   4   9   5
Affiliations

Spatially resolved transcriptomics of benign and malignant peripheral nerve sheath tumors

Juliane Bremer et al. Neuro Oncol. .

Abstract

Background: Peripheral nerve sheath tumors (PNSTs) encompass entities with different cellular differentiation and degrees of malignancy. Spatial heterogeneity complicates the diagnosis and grading of PNSTs in some cases. In malignant PNST (MPNST) for example, single-cell sequencing data has shown dissimilar differentiation states of tumor cells. Here, we aimed to determine the spatial and biological heterogeneity of PNSTs.

Methods: We performed spatial transcriptomics on formalin-fixed paraffin-embedded diseased peripheral nerve tissue. We used spatial clustering and weighted correlation network analysis to construct niche-similarity networks and gene expression modules. We determined differential expression in primary pathologies, analyzed pathways to investigate the biological significance of identified meta-signatures, integrated the transcriptional data with histological features and existing single-cell data, and validated expression data by immunohistochemistry.

Results: We identified distinct transcriptional signatures differentiating PNSTs. Immune cell infiltration, APOD, and perineurial fibroblast marker expression highlighted the neurofibroma component of hybrid PNSTs (HPNSTs). While APOD was evenly expressed in neurofibromatous tumor tissue in both, HPNST and pure neurofibromas, perineurial fibroblast markers were evenly expressed in HPNST, but restricted to the periphery in plexiform neurofibromas. Furthermore, we provide a spatial cellular differentiation map for MPNST, locating Schwann cell precursor and neural crest-like cells as well as those with mesenchymal transition.

Conclusions: This pilot study shows that applying spatial transcriptomics to PNSTs provides important insight into their biology. It helps establish new markers and provides spatial information about the cellular composition and distribution of cellular differentiation states. By integrating morphological and high-dimensional molecular data it can improve PNSTs classification in the future.

Keywords: biomarker; peripheral nerve sheath tumors; spatial transcriptomics.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interests to disclose.

Comment in

References

    1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251. - PMC - PubMed
    1. Capone C, Turrini A, Rossi G, et al. Monophasic synovial sarcoma mimicking schwannoma: a case report of a rare peripheral nerve tumor and literature review. Neurol Res. 2023;45(6):530–537. - PubMed
    1. Ferner RE, Gutmann DH.. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002;62(5):1573–1577. - PubMed
    1. Miettinen MM, Antonescu CR, Fletcher CDM, et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum Pathol. 2017;67:1–10. - PMC - PubMed
    1. Pemov A, Hansen NF, Sindiri S, et al. ; National Intramural Sequencing Center (NISC) Comparative Sequencing Program. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas. Neuro Oncol. 2019;21(8):981–992. - PMC - PubMed

Substances

LinkOut - more resources